Monday, April 29, 2024

4:30 PM - 5:00 PM

Room 11C

---

Details

Preventing, recognising and managing delayed methotrexate (MTX) elimination is paramount in haemato-oncology patients treated with high-dose methotrexate (HDMTX). Despite appropriate adjunctive measures and monitoring, some patients may still experience nephrotoxicity following HDMTX administration. A clear understanding of the potential risk factors of individual patients, extensive monitoring and preparedness for prompt intervention can help prevent potentially irreversible life-threatening toxicity. This promotional symposium is funded and organised by SERB pharmaceuticals.

---

Speaker